ORMP
What one share of Oramed Pharmaceuticals holds
Pharmaceutical Preparations
We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we believe complement our long-term business objectives and technology focus.
Oramed Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $4.14 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.12 |
| Cash and investments | $0.92 |
| Book value | $7.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.13 | $0.56 | $0.00 | −$0.61 | — | $1.39 |
| 2021 | $0.09 | $0.78 | $0.01 | −$0.76 | — | $3.28 |
| 2022 | $0.07 | −$0.94 | $0.01 | −$0.73 | — | $3.84 |
| 2023 | $0.03 | $0.14 | $0.01 | −$0.26 | — | $4.06 |
| 2024 | — | −$0.47 | $0.00 | −$0.21 | — | $3.66 |
| 2025 | $0.05 | $1.50 | $0.00 | −$0.22 | $0.25 | $5.09 |